Andrew Anzalone, MD, PhD
Co-Founder and Head of Platform, Prime Medicine
Andrew Anzalone, MD, PhD is listed as Co-Founder and Head of Platform, Prime Medicine. Andrew is scheduled to speak at Tides 2027 on 26 April 2027.
Compiled from published conference agendas; not yet confirmed by Andrew. Is this you? Claim this profile.
About
Andrew Anzalone joined Prime Medicine in 2020 as the head of the prime editing platform, where he currently leads efforts to advance technological developments in prime editing for human therapeutic applications. Dr. Anzalone received his Sc.B. degree in chemistry from Brown University, where he performed undergraduate research in synthetic organic chemistry. He completed his M.D. and Ph.D. degrees at Columbia University as part of the Medical Scientist Training Program. Dr. Anzalone’s thesis research in Virginia W. Cornish’s laboratory focused on the design and synthesis of fluorescent probes for biological imaging applications, and on the investigation and engineering of RNA-dependent protein translation reprogramming mechanisms in eukaryotes. After completing his graduate studies, Dr. Anzalone pursued postdoctoral research as a Jane Coffin Childs Memorial Fund Postdoctoral Fellow in the laboratory of David R. Liu at the Broad Institute of Harvard and MIT. In the Liu laboratory, Dr.
Upcoming
Tides 2027 26 April 2027 – 29 April 2027
Announced as a speaker.